Document is current
Any future updates will be listed below
-
Authors
,
Schäfer, Guido http://orcid.org/0000-0002-0983-4234
Hoffmann, Christian
Arasteh, Keikawus
Schürmann, Dirk
Stephan, Christoph
Jensen, Björn
Stoll, Matthias
Bogner, Johannes R.
Faetkenheuer, Gerd
Rockstroh, Jürgen
Klinker, Hartwig
Härter, Georg
Stöhr, Albrecht
Degen, Olaf
Freiwald, Eric
Hüfner, Anja
Jordan, Sabine
Schulze zur Wiesch, Julian
Addo, Marylyn
Lohse, Ansgar W.
van Lunzen, Jan
Schmiedel, Stefan
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb Foundation
- License Information
-
More Information
Article History
Received: 13 August 2019
Accepted: 26 October 2019
First Online: 15 November 2019
Ethics approval and consent to participate
: All participating sites had local ethical approval according to national laws. All subjects provided written informed consent.
: All mentioned authors gave their consent for publication.
: Johannes R. Bogner received honorary for advisory boards and lecturing from AbbVie, ViiV, MSD, Gilead, Janssen, BMS, Hexal. Christian Hoffmann has received honoraria for lecturing, advisory boards and travelling grants and research grants from AbbVie, Bristol Myers-Squibb, Boehringer-Ingelheim, Gilead Sciences, HEXAL, Hormosan, Janssen-Cilag, MSD, Teratech and ViiV Healthcare. Gerd Faetkenheuer received lecture fees, honorary for advisory boards, and travel and research grants: Bristol Myers Squibb, Gilead, Merck Sharp & Dohme. Jan van Lunzen has received honoraria for lecturing, advisory boards and travelling grants from AbbVie, Bristol Myers-Squibb, Boehringer-Ingelheim, Gilead Sciences, HEXAL, Janssen-Cilag, MSD, Teratech and ViiV Healthcare. Christoph Stephan received financial support, related to scientific projects by MSD, BMS, AbbVie and received honorary for lectures or scientific advisory boards from: Abbott, BMS, ViiV, Gilead, Janssen, Roche. Juergen Rockstroh has received honoraria for consulting or speaking at educational events from Abbvie, BMS, Gilead, Merck, Janssen and ViiV. Olaf Degen received honoraria for lecturing, advisory boards and travelling grants from ViiV, GSK, Gilead, BMS, Janssen-Cilag. Matthias Stoll received honoraria as advisor, lecturer or funding of studies by Abbott, Abbvie, Boehringer-Ingelheim, Bristol-Myers-Squibb, Gilead, Glaxo-Smith-Kline, Hexal, Hormosan, Janssen-Cilag, Merck, Sharp & Dohme, Novartis, Pfizer, Roche, Tibotec, ViiV, Viro-Pharmaceuticals. All other authors declare that they have no competing interests.
